Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2020-05-05
2020-07-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Spironolactone
2 x 100 mg spironolactone
Spironolactone 100mg
2x100 mg spironolactone for 5 consecutive days
Placebo
2 x 1 placebo
Placebo oral tablet
2 x1 placebo tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone 100mg
2x100 mg spironolactone for 5 consecutive days
Placebo oral tablet
2 x1 placebo tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypoxemia, i.e. p/f \<150
* Admitted to ICU within 48 hours
* Not moribund has a life expectancy greater than 24 hours
Exclusion Criteria
* Pregnancy
* Unwillingness to participate
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University - Cerrahpasa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olcay Dilken
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yalim Dikmen
Role: STUDY_DIRECTOR
Prof
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul University-Cerrahpaşa
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10042020
Identifier Type: -
Identifier Source: org_study_id